Catalyst Pharmaceuticals Inc (CPRX) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

CPRX ranks #1554 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

395 institutions disclose a position in CPRX, but none treat it as a major bet — even Gables Capital Management Inc., its most concentrated holder, allocates just 4.8% of its own portfolio to it.

BlackRock has added to its CPRX position for two straight quarters, increasing it by $167.4M to reach $602.2M today.

Invesco Ltd. has trimmed its CPRX position for two straight quarters, cutting it by $16.2M while still holding $14.0M.

CPRX posted net income of $221.3M over the trailing twelve months.

• Profitable — net income of $221.3M over the trailing twelve months
• Revenue grew 11.7% year over year
• Net income improved year over year, from $197.4M to $221.3M
• Generated $208.7M in positive operating cash flow
• Current ratio of 6.08x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.16x equity — within a conventional range